| Literature DB >> 23072542 |
Rakhee N Urankar1, Robert M Lust, Erin Mann, Pranita Katwa, Xiaojia Wang, Ramakrishna Podila, Susana C Hilderbrand, Benjamin S Harrison, Pengyu Chen, Pu Chun Ke, Apparao M Rao, Jared M Brown, Christopher J Wingard.
Abstract
BACKGROUND: The exceptional physical-chemical properties of carbon nanotubes have lead to their use in diverse commercial and biomedical applications. However, their utilization has raised concerns about human exposure that may predispose individuals to adverse health risks. The present study investigated the susceptibility to cardiac ischemic injury following a single exposure to various forms of multi-walled carbon nanotubes (MWCNTs). It was hypothesized that oropharyngeal aspiration of MWCNTs exacerbates myocardial ischemia and reperfusion injury (I/R injury).Entities:
Mesh:
Substances:
Year: 2012 PMID: 23072542 PMCID: PMC3518151 DOI: 10.1186/1743-8977-9-38
Source DB: PubMed Journal: Part Fibre Toxicol ISSN: 1743-8977 Impact factor: 9.400
MWCNT Characteristics
| C-grade | 22.5 ± 1.3 | 10 - 100 | 0.29 | 4.80 | C = 99.6 N = 0.0
O = 0.0 Fe = 0.04 | 113.10 | 0.69 |
| COOH | 19.1 ± 1.6 | 40 - 100 | 0.35 | 5.15 | C = 96.5 N = 0.0
O = 3.5 Fe = 0.07 | 111.39 | 0.60 |
| N-doped | 23.3 ± 1.5 | 50 - 80 | 0.93 | 3.68 | C = 80.8 N = 19.2 O = 0.0 Fe = 0.04 | 140.15 | 0.93 |
Figure 1Representative electron micrographs of the Commercial grade (C-grade, Panel A), carboxylated (COOH, Panel B) and Nitrogen doped (N-doped, Panel C) MWCNTs. Left hand panels are scanning EM (SEM) of the bulk dry CNTs. Right hand panels are transmission EM (TEM) of MWCNT in suspension. Black arrows indicate presence of Fe metal catalyst inclusion within the MWCNT. Red arrows identify bamboo structure in N-doped MWNCTs.
MWCNT Suspension Characteristics
| C-grade | - 44.6 mV | 3.5 pH | 180 ± 50 nm and 1100 ± 200 nm |
| COOH | - 37.9 mV | 2.0 pH | 140 ± 50 nm and 700 ± 150 nm |
| N-doped | - 40.6 mV | 3.0 pH | 150 ± 50 nm and 1300 ± 250 nm |
Pulmonary Bronchoalveolar Lavage Fluid Protein (μg/ml)
| SS | | 0.07 ± 0.01 | 0.03 ± 0.01 | 0.15 ± 0.01 |
| C-grade | 1 μg | 0.18 ± 0.01* | 0.08 ± 0.01 | 0.12 ± 0.02 |
| | 100 μg | 0.27 ± 0.04*† | 0.12 ± 0.03 | 0.12 ± 0.01 |
| COOH | 1 μg | 0.19 ± 0.02 | 0.07 ± 0.01 | 0.12 ± 0.01 |
| | 100 μg | 0.30 ± 0.14 | 0.12 ± 0.03 | 0.12 ± 0.01 |
| N-doped | 1 μg | 0.22 ± 0.02* | 0.05 ± 0.01 | 0.17 ± 0.01 |
| 100 μg | 0.24 ± 0.04* | 0.09 ± 0.01 | 0.19 ± 0.01 |
Bronchoalveolar lavage fluid (BALF) protein levels (μg/ml) following oropharyngeal aspiration of three forms of MWCNTs at 1μg and 100 μg or SS vehicle control (10% surfactant saline). The protein levels were performed on pooled aliquots of the BALF at 1 day, 7 day and 28 day post aspiration. Data reported as mean ± SEM for n = 4. * indicates significance from SS, † indicates significance from 1 μg dose within the same MWCNT form, P ≤ 0.05.
Pulmonary BALF Cell Counts at 1, 7 and 28 Days Following Oropharyngeal Aspiration of MWCNTs
| SS | | 1.80 ± 0.15 | 1.49 ± 0.12 | 0.01 ± 0.01 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.29 ± 0.03 |
| C-grade | 1 μg | 2.25 ± 0.25 | 0.76 ± 0.08 | 1.65 ± 0.21 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.09 ± 0.01 |
| | 100 μg | 4.64 ± 0.60* | 1.12 ± 0.13 | 3.36 ± 0.71* | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.14 ± 0.05 |
| COOH | 1 μg | 4.19 ± 0.45 | 1.42 ± 0.08 | 2.60 ± 0.38* | 0.01 ± 0.01 | 0.0 ± 0.0 | 0.14 ± 0.02* |
| | 100 μg | 5.30 ± 1.57* | 1.25 ± 0.35 | 3.92 ± 1.38* | 0.08 ± 0.04 | 0.0 ± 0.0 | 0.03 ± 0.01* |
| N-doped | 1 μg | 7.16 ± 0.24* | 2.06 ± 0.35 | 4.75± 0.27* | 0.01 ± 0.01 | 0.0 ± 0.0 | 0.27 ± 0.04 |
| | 100 μg | 6.22 ± 1.14* | 1.84 ± 0.40 | 4.21 ± 0.75* | 0.05 ± 0.02 | 0.0 ± 0.0 | 0.15 ± 0.01 |
| SS | | 4.44 ± 0.15 | 4.20 ± 0.14 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.03 ± 0.01 | 0.19 ± 0.01 |
| C-grade | 1 μg | 4.78 ± 1.21 | 4.46 ± 1.17 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.31 ± 0.13 |
| | 100 μg | 2.80 ± 0.72 | 2.53 ± 0.67 | 0.04 ± 0.01 | 0.03 ± 0.01 | 0.0 ± 0.0 | 0.18 ± 0.07 |
| COOH | 1 μg | 1.33 ± 0.08 | 1.07 ± 0.08* | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.25 ± 0.03 |
| | 100 μg | 3.15 ± 0.05 | 2.63 ± 0.12* | 0.19 ± 0.08 | 0.12 ± 0.06 | 0.03 ± 0.01 | 0.16 ± 0.01 |
| N-doped | 1 μg | 5.61 ± 1.67 | 5.04 ± 1.52 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.06 ± 0.04 | 0.49 ± 0.16 |
| | 100 μg | 4.92 ± 0.75 | 4.35 ± 0.86 | 0.03 ± 0.03 | 0.0 ± 0.0 | 0.07 ± 0.04 | 0.46 ± 0.09 |
| SS | | 1.30 ± 0.24 | 1.24 ± 0.20 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.06 ± 0.03 |
| C-grade | 1μg | 1.04 ± 0.35 | 0.87 ± 0.26 | 0.0 ± 0.0 | 0.01 ± 0.01 | 0.0 ± 0.0 | 0.15 ± 0.07 |
| | 100 μg | 1.48 ± 0.29 | 1.37 ± 0.27 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.01± 0.01 | 0.10 ± 0.02 |
| COOH | 1μg | 1.29 ± 0.07 | 1.15 ± 0.08 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.13± 0.02 |
| | 100 μg | 1.74 ± 0.23 | 1.60 ± 0.22 | 0.02 ± 0.01 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.10 ± 0.01 |
| N-doped | 1 μg | 0.92 ± 0.29 | 0.86 ± 0.28 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.06 ± 0.04 | 0.05 ± 0.01 |
| 100 μg | 1.27 ± 0.11 | 1.15 ± 0.10 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.07 ± 0.04 | 0.11 ± 0.01 | |
Bronchoalveolar lavage fluid cell counts following oropharyngeal aspiration of three forms of MWCNTs at 1μg and 100 μg or SS vehicle control (10% surfactant saline). The cell counts were performed at 1 day, 7 day and 28 day post-instillation. Data reported as mean ± SEM for n = 4. * indicates significance from SS, † indicates significance from 1 μg dose in same MWCNT form, P ≤ 0.05.
Figure 2Representative histological sections of the left lung 1 day post oropharyngeal aspiration of vehicle control (SS) and 100 μg of each of the MWCNT forms: Commercial grade (C-grade), Carboxylated (COOH) and Nitrogen doped (N-doped). Images are of H&E stained 8μm thick cross-sections of left lung. Larger panel images were captured at 10x magnification and inset images at 40x magnification. Arrows indicate deposits of MWCNT.
Blood Cell Counts 1 Day post Oropharyngeal Aspiration of 100 μg MWCNTs
| Total WBC Count (10^3/μl) | 4.18 ± 0.27 | 3.75 ± 0.45 | 5.03 ± 0.68 | 4.4 ± 0.21 |
| Neutrophils | 0.45 ± 0.06 | 0.40 ± 0.08 | 0.81 ± 0.08 *†# | 0.40 ± 0.03 |
| Lymphocytes | 3.49 ± 0.24 | 3.04 ± 0.33 | 3.78 ± 0.56 | 3.72 ± 0.17 |
| Monocytes | 0.19 ± 0.03 | 0.22 ± 0.05 | 1.13 ± 0.86 | 0.25 ± 0.05 |
| Eosinophils OO | 0.03 ± 0.01 | 0.07 ± 0.01 | 0.04 ± 0.01 | 0.01 ± 0.01 |
| RBC Count (10^6/μl) | 8.49 ± 0.22 | 8.82 ± 0.28 | 8.91 ± 0.23 | 8.74 ± 3.07 |
| PTL Count (10^3/μl) | 1091.5 ± 79.8 | 771.3 ± 151.1 | 977.3 ± 102.3 | 980.3 ± 66.0 |
Blood Cell Counts following oropharyngeal aspiration of three forms of MWCNTs at 100 μg or SS vehicle control (10% surfactant saline). The cell counts were performed at 1 day post aspiration. Data reported as mean ± SEM for n = 6. * indicates significance from SS, † indicates significance from C-grade and # from N-doped MWCNT by one way ANOVA, P ≤ 0.05.
Serum Cytokine Profile 1 Day post Oropharyngeal Aspiration of 100 μg MWCNTs (pg/ml)
| Eotaxin | 306.4 ± 75.0 | 276.9 ± 42.3 | 903.8 ± 278.6* | 302.6 ± 22 |
| IL-5 | 16.3 ± 1.1 | 30.3 ± 10.0 | 11.6 ± 3.0 | 51.2 ± 28.3 |
| IL-6 | 9.2 ± 1.3 | 16.1 ± 7.8 | 137.8 ± 66.0 | 42.4 ± 26.4 |
| IL-10 | 8.5 ± 1.9 | 8.6 ± 3.4 | 24.6 ± 15.4 | 125.8 ± 118.1 |
| IL-12 (p40) | 17.5 ± 3.6 | 20.3 ± 5.3 | 16.3 ± 2.2 | 12.6 ± 2.2 |
| IL-12 (p70) | 35 ± 5.9 | 55.3 ± 34.9 | 22.9 ± 3.1 | 516.7 ± 464.5 |
| IL-13 | 446.3 ± 41.6 | 326.9 ± 38.2 | 365.3 ± 45.6 | 848.3 ± 490.0 |
| KC | 173.2 ± 32.6 | 97.1 ± 7.1 | 645.1 ± 441.3 | 183.5 ± 53.1 |
| MCP-1 | 39.6 ± 12.3 | 36.6 ± 8.6 | 46.6 ± 6.0 | 136.1 ± 104.4 |
| MIP1α | 38.2 ± 9.3 | 71.1 ± 4.5 | 42.0 ± 4.4 | 128.1 ± 86.9 |
| MIP-1β | 129.0 ± 11.4 | 70.2 ± 22.3 | 82.8 ± 29.6 | 136.2 ± 48.8 |
| MIP-2 | 155.4 ± 27.7 | 86.4 ± 43.8 | 209.1 ± 38.9 | 102.4 ± 26.4 |
| RANTES | 30.7 ± 5.8 | 36.1 ± 6.4 | 57.5 ± 12.0 | 65.9 ± 38.5 |
| †IL-1β | 33.25 ± 3.83 | 222.86 ±114.71 | 127.66 ± 45.32 | 47.25 ± 7.36 |
| †TNF-α | N.D. | N.D. | N.D. | N.D. |
Serum cytokine profile by Lincoplex Cytokine/Chemokine 20 plex kit 1 day post oropharyngeal aspiration of three forms of MWCNTs at 100 μg and vehicle control SS (10% surfactant saline). Data reported as mean ± SEM for n = 4. * indicates significance from SS, P ≤ 0.05.
† IL-1β and TNF-α profile 1 day post oropharyngeal aspiration of three forms of MWCNTs at 100 μg and vehicle control SS (10% surfactant saline) by ELISA. Data reported as mean ± SEM for n = 6. N.D. not detected, P ≤ 0.05 by one way- ANOVA.
Figure 3The time-dependent cardiac ischemic-reperfusion (I/R) injury following vehicle control 10% surfactant/saline (SS) and 100 μg of each of the three forms of MWCNT: Commercial grade (C-grade), carboxylated (COOH) and nitrogen doped (N-doped). The cardiac I/R injuries were performed at 1 day (A), 7 day (B) and 28 day (C) post oropharyngeal aspiration of 100 μl of the MWCNT suspension. Data are reported as mean ± sem with an n = 6. * indicates statistical significance from the SS group and † represent statistical significance from the c-grade group by ANOVA with TUKEY post hoc analysis with significance at p < 0.05.
Figure 4Graphs depicting the extent time- and dose-dependent cardiac ischemic reperfusion (I/R) injury following oropharyngeal aspiration of vehicle control 10% surfactant/saline (SS) and 3 forms of the MWCNT: Commercial grade (C-grade) Row A, carboxylated (COOH) Row B and nitrogen doped (N-doped) Row C. The cardiac I/R injuries were performed at 1 day (left most panels), 7 day (middle panels) and 28 day (right most panels) post aspiration of 100 μl of the MWCNT suspension. Data are reported as mean ± sem with an n = 6. * indicates statistical significance from the SS group, § from 0.01 μg, † from 0.1 μg ‡ from 1.0 μg and # from 10 μg dosing as determined by ANOVA with TUKEY post hoc analysis with significance at p < 0.05.